Fulvestrant Powder Pharmaceutical Raw Materials Drugs for Breast Cancer

» Farmacéutico » Fármacos antitumorales » Fulvestrant Powder Pharmaceutical Raw Materials Drugs for Breast Cancer

  • Presupuesto

Buy Fulvestrant Powder Selective Estrogen Receptor Degrader Drug for Breast Cancer Online


Fulvestrant Specification

nombre del producto: Fulvestrant
CAS: 129453-61-8
Estándar: USP35
Natural/Synthetic: Synthetic
Nivel: Grado farmacéutico
Contenido: 99%
Apariencia: polvo blanco
Embalaje: 10G/Aluminum foil bag
Categoría: Materias primas farmacéuticas
Industria: productos farmacéuticos
Campo: Steroid anti-estrogen drugs
producto diferida: Fulvestrant injection
Utilizar: Estrogen receptor-positive locally advanced or metastatic mammary glands that can be used after anti-estrogen adjuvant therapy or during treatment, or after menopause (including natural menopause and artificial menopause) in anti-estrogen therapy cancer.
Usage and dosage: 1. Adult females (including elderly women): The recommended dose is once a month, once 250mg. There is a lack of information on the safety and efficacy of Chinese patients at higher doses. 2. Children and Adolescents: Since the safety and effectiveness of this product in children and adolescents have not been determined, the use of this product in this age group is not recommended. 3. Patients with impaired renal function: For patients with mild-to-moderate renal impairment (creatinine clearance ≥ 30 ml/min), there is no need to adjust the dose.


What is Fulvestrant?

Fulvestrant is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.

Fulvestrant is given by injection into a muscle.


Fulvestrant Certificate of Analysis

Nombre del producto Fulvestrant
CAS No. 129453-61-8 Embalaje externo 10g/foil bag
Fecha de producción 2017-10-22 Duracion 2019-10-18
norma adoptada USP35
Los productos de análisis Especificación resultados
Apariencia A white to off-white crystalline powder En cumplimiento
Identificación 1、IR IR should conform to the standard En cumplimiento
Specific rotaion +108°~ +115° 110.8°
6-Keto Fulvestran ≤0.1% 0.05%
∆6,7-Fulvestran ≤0.1% 0.08%
Fulvestrant sulfone ≤0.2% 0.11%
Fulvestrant extended ≤0.3% 0.08%
Fulvestrant sterol dimmer ≤0.8% 0.09%
Fulvestrant β-isomer ≤0.1% 0.06%
Any individual unspecified impurity ≤0.1% 0.03%
Total impurity ≤1.0% 0.7%
FulvestrantA 42%~48% 45.42%
FulvestrantB 52%~58% 54.58%
Residuo de Lgnition ≤0.1% 0.03%
Drying loss ≤0.5% 0.30%
Agua ≤0.5% 0.26%
Ensayo 98.0%~102% 99.2%
Conclusión Calificado


Fulvestrant Side Effects

Very common (occurring in more than 10% of people) adverse effects include nausea, injection site reactions, weakness, and elevated transaminases. Common (between 1% y 10%) adverse effects include urinary tract infections, hypersensitivity reactions, loss of appetite, headache, blood clots in veins, hot flushes, vomiting, Diarrea, elevated bilirubin, rashes, and back pain.

Sales Contacts

Tel/Whatsapp: +86 17707567122
Wickr: mollyying
Telegrama: +86 185785209851
Skype: ying_2073
Mail: ying@wumeitech.com

Formulario de Consulta ( vamos a ayudarle a volver tan pronto como sea posible )


3 + 9 = ?

Tal vez como también

  • Categorías de Producto

  • Mensajes recientes

  • Compartir